• Contact us
  • Suomeksi

Search
  • HOME
  • INVESTORS
    • Investors
    • Why to invest?
    • Miksi sijoittaa?
    • Head injuries in sports and army
    • PowerPoint presentation
    • Executive summary
    • Financials
    • Investment agreement
  • TECHNOLOGY
    • Technology
    • Indication
    • Science
    • Biomarker R&D program
      • Proof of concept
      • Second clinical trial
      • Assay development plan
    • Drug development program
    • IP rights
  • COMPANY PROFILE
    • Company Profile
    • Our Vision
    • Business Strategy
    • Board and Management
    • Partners
  • NEWS & EVENTS
    • News & events
    • News archive
    • In the Press
      • Drug Target Review
      • Kansanterveys
      • Medicortex in Good News Finland
      • Science Park Medicortex Finland
      • Turkuposti
    • Articles
  • CONTACT US

Search

Search






Search results

Business Strategy(Page)
de. Business Strategy ABI,Crowd funding,TBI...

Most used keywords

FinancingInvestorSABABITBIAivovammaEquityMedicortexR&DUnrheiluvammaBiomarkerCrowd fundingNCEBBBArtAivovaurioAivohalvaus
Medicortex Finland Oy
Pharma City
Itäinen Pitkäkatu 4 B, 4th floor
FI-20520 Turku, Finland
Tel. +358 (0)400 488817
Fax. +358 (0)2 251 0100
adrian.harel@medicortex.fi
  • Contact us
  • Suomeksi

Search
  • INVESTORS
  • Why to invest?
  • Miksi sijoittaa?
  • Head injuries in sports and army
  • PowerPoint presentation
  • Executive summary
  • Financials
  • Investment agreement
  • TECHNOLOGY
  • Indication
  • Science
  • Biomarker R&D program
  • Drug development program
  • IP rights
  • COMPANY PROFILE
  • Our Vision
  • Business Strategy
  • Board and Management
  • Partners
  • NEWS & EVENTS
  • News archive
  • In the Press
  • Articles
  • CONTACT US
VERKKOVARAANI